Novartis and GSK Advertised the Suitability of Their Brands for MF Early Therapy in Europe during Q3 2025

Market Highlights

  • In the European myelofibrosis market, direct mail and medical education were the most utilized promotional channels, mainly aimed at French physicians. Most materials were distributed in digital form.
  • Novartis’s Jakavi celebrated 10 years of clinical experience and advertised its benefits, supported by several clinical studies, including early therapy, while promoting online platforms to guide HCPs. The “Pendulum” campaign theme was introduced.
  • GSK promoted the approval and launch of Omjjara, a once-daily oral treatment for MF patients with moderate-to-severe anemia. Its mechanism of action was noted, along with the advantages of early use to address all three core manifestations of MF. The “Ampersand” and the “Three Manifestations” campaigns were observed.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com